Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7398081 | 0.86 | SIGMAR1 (0.50) | SIGMAR1DRD2HRH3 | |
| SCHEMBL7393414 | 0.85 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL7401016 | 0.79 | DRD2 (0.66) | DRD2HRH3 | |
| SCHEMBL7402278 | 0.76 | DRD2 (0.50) | DRD2HRH3 | |
| SCHEMBL7401581 | 0.75 | CYP2J2 (0.48) | DRD2 | |
| SCHEMBL7394943 | 0.74 | SIGMAR1 (0.52) | SIGMAR1 | |
| SCHEMBL7402939 | 0.72 | SIGMAR1 (0.75) | SIGMAR1DRD2 | |
| SCHEMBL7399263 | 0.72 | MAOA (0.51) | DRD2 | |
| SCHEMBL8091036 | 0.69 | SIGMAR1 (0.76) | SIGMAR1DRD2KCNA3 | |
| SCHEMBL14266745 | 0.68 | MAOA (0.49) | DRD2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5206233-A | Antidepressants, antiischemic agents | WARNER-LAMBERT COMPANY (US) | 1993-04-27 | — | — | US | claimed |
| WO-1993004053-A1 | SUBSTITUTED THIAZEPINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | claimed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | disclosed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |
| US-5206233-A | Antidepressants, antiischemic agents | WARNER-LAMBERT COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| WO-1993004053-A1 | SUBSTITUTED THIAZEPINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |